Navigation Links
Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
Date:8/21/2008

SAN DIEGO, Aug. 21 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has authorized a Phase 1 study evaluating RDEA594 in normal healthy volunteers. RDEA594 is the Company's lead product candidate for the treatment of gout.

"Regulatory clearance for us to proceed with our Phase 1 study of RDEA594, within six months from designation as a clinical candidate is a testament to the efficiency of our development organization, and the importance we place on our gout program -- a program we intend to expand with second-generation compounds from our exciting ongoing research in this area," said Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "Earlier this quarter, we initiated a Phase 2a proof-of-concept study of RDEA806, a prodrug of RDEA594, which should allow us to provide an early confirmation of RDEA594's activity in the target population of patients with gout."

This Phase 1, randomized, double-blind, placebo-controlled trial will evaluate the safety, tolerability, pharmacokinetics and uric acid lowering effects of single ascending oral doses of RDEA594 in healthy adult male volunteers.

About Gout

An estimated 3-5 million people in the United States, and approximately 5 million people in the European Union, suffer from gout, which is the most common form of inflammatory arthritis in men over 40. Gout, also known as metabolic arthritis, is a painful and debilitating disease caused by abnormally elevated levels of uric acid in the blood stream. These abnormally elevated levels lead to the deposition of uric acid crystals in and around the connective tissue of the joints and in the kid
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...AM, Mass. and NEW YORK, Dec. 2 /PRNewswire-FirstCa... ) and NYU Langone Medical Center announced findin...ke University on the genetics of osteoarthritis ha...version of the Annals of Rheumatic Diseases and is....2009.113043v1.pdf . Results from the study hi...
(Date:12/2/2009)...LE, Md., Dec. 2 Novavax,...itial results from the first stage of a two-stage ...mmunogenicity of the company,s 2009 H1N1 virus-lik...vax is conducting this study in collaboration with...tion of the vaccine in Mexico and potentially othe...
(Date:12/2/2009)...HAM, Ala., Dec. 2 Adults are mor...th cancer. For adults 65 and over, the odds of los... man developing prostate cancer are one in six and...in nine. Vision loss threatens the overall health...s, depression and inability to complete daily task...
Breaking Medicine Technology:Interleukin Genetics and NYU Langone Medical Center Announce Publication of Study on Genetics of Osteoarthritis 2Interleukin Genetics and NYU Langone Medical Center Announce Publication of Study on Genetics of Osteoarthritis 3Interleukin Genetics and NYU Langone Medical Center Announce Publication of Study on Genetics of Osteoarthritis 4NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 2NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 3NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 4Risk of Vision Loss in Aging Adults is Greater Than Risk of Breast or Prostate Cancer 2Health Plans Prepare for Health Care Reform 3A Comparative Effectiveness Consumerism Drive Future Changes According to Deloitte Study 47924 1Health Plans Prepare for Health Care Reform 3A Comparative Effectiveness Consumerism Drive Future Changes According to Deloitte Study 47924 2Health Plans Prepare for Health Care Reform 3A Comparative Effectiveness Consumerism Drive Future Changes According to Deloitte Study 47924 3Health Plans Prepare for Health Care Reform 3A Comparative Effectiveness Consumerism Drive Future Changes According to Deloitte Study 47924 4Health Plans Prepare for Health Care Reform 3A Comparative Effectiveness Consumerism Drive Future Changes According to Deloitte Study 47924 5Anadys Pharmaceuticals Inc Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 12473 1Anadys Pharmaceuticals Inc Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 12473 2Anadys Pharmaceuticals Inc Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 12473 3Anadys Pharmaceuticals Inc Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 12473 4Anadys Pharmaceuticals Inc Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 12473 5Over 60 percent of all US bankruptcies attributable to medical problems 47917 1Over 60 percent of all US bankruptcies attributable to medical problems 47917 2
... Data from five studies presented at United Europe... (UEGW) -, - Non-invasive imaging system di...gastrointestinal tract safely and effectively -, ...leader,in the field of in vivo cellular imaging, a... presented five abstracts related to the company,s...
...RSA Scorecard Provides Hospital-Wide View of MRSA ...h, a,global provider of products and services that...e, today announced a new service to help,hospitals...s (MRSA),infections that are responsible for an es...650 deaths annually in the U.S.(1) Cardinal Healt...
Other Medicine Technology:New Clinical Studies Confirm Mauna Kea Technologies' Cellvizio(R) GI in Range of Procedures 2New Clinical Studies Confirm Mauna Kea Technologies' Cellvizio(R) GI in Range of Procedures 3New Clinical Studies Confirm Mauna Kea Technologies' Cellvizio(R) GI in Range of Procedures 4New Clinical Studies Confirm Mauna Kea Technologies' Cellvizio(R) GI in Range of Procedures 5Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals 2Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals 3
(Date:12/2/2009)...on Post Highlights Dangers ,, WASHINGTON, D...c bishops have their way, many medical treatments ...be under threat. The pressure that the US bishops...e reform has been widely reported. An ad in this m...act if that pressure to influence healthcare polic...
(Date:12/2/2009)...-- Proving true the old adage that "The sum is gre...t Hospital Southlake (THHMHS) is partnering with t...m to make the holiday season a little brighter for...ing their efforts to collect unwrapped toys and ca...lminating in a final event on Tuesday, December 8...
(Date:12/2/2009)...mong youths are more likely to be advertised in ma...drinks consumed mainly by adults, resulting in dis...ed alcohol ads, according to a new study. , Rese...Health, Johns Hopkins Bloomberg School of Public H...he study -- published in this month,s issue of th...
(Date:12/2/2009)...high cholesterol and become obese? The same way as...ts. , More importantly, according to two new stu... fruit flies use the same molecular mechanisms as ...erol and a key form of stored fat that contributes... try to learn more about the genetic and biologica...
(Date:12/2/2009)...ire/ -- Holly Potter, vice president, Public Relat...r Kaiser Permanente, received the "PR Team Leader"...e National Press Club. ,, PR News, PR Peopl...and professionals who day in and day out are makin...nners of this year,s program set the benchmark for...
Breaking Medicine News(10 mins):Health News:Everybody's Healthcare Is Threatened by Catholic Bishops' Interference 2Health News:Texas Health Harris Methodist Hospital Southlake Joins With U.S. Marine Corps Reserves Toys for Tots to Spread Holiday Cheer 2Health News:Alcohol companies target youths with magazine ads, new study shows 2Health News:Latest epidemic? High cholesterol, obesity in fruit flies 2Health News:Latest epidemic? High cholesterol, obesity in fruit flies 3Health News:Kaiser Permanente Public Relations Leader Wins PR People Award 2Health News:Kaiser Permanente Public Relations Leader Wins PR People Award 3
...s Will Address Medical Device Clinical Trials, Reg...RTH ATTLEBORO, Mass., Feb. 5 MDCI, a full-service...l device industry, today announced that it has nam...vices. In his new role, Michael will provide high-...
...tant new guidelines for dentists using the latest ...s have been established for UK and European practi...which gives a similar kind of image as a medical C...T carries an increased risk associated with greate...
... friendship, even love, can be just one click away... married thanks to internet dating. From its dubio...mn has become big business and an acceptable way o...ling the story of how we finally learned to love t...
...DIANAPOLIS, Feb. 5 WellPoint, Inc. commends Presi...of the State Children,s Health,Insurance Program (...ditional,resources to ensure that all eligible chi...public and,private sectors. The reauthorization of...
...of the substances in our most common medicines are...ctories release large quantities of antibiotics an...nt. There is an obvious risk of these releases lea...rmaceutical substances from factories that fail to...
... WASHINGTON, Feb. 5 The Milwaukee Journal Sentine...ard for Excellence in Health Journalism from the B...on Making. The Foundation, which presented the awa...sReview.org. That web-based project, funded by the...
Other Medicine News:Health News:Medical Device Consultants, Inc. (MDCI) Announces Senior Staff Changes and Promotions 2Health News:Classified -- the lonely heart's long road to respectability 2Health News:WellPoint Applauds President Obama for Signing SCHIP Reauthorization 2Health News:Pharmaceuticals sold in Sweden cause serious environmental harm in India 2Health News:Pharmaceuticals sold in Sweden cause serious environmental harm in India 3Health News:Milwaukee Journal Sentinel Wins First Health Journalism Award from Foundation for Informed Medical Decision Making 2Health News:Milwaukee Journal Sentinel Wins First Health Journalism Award from Foundation for Informed Medical Decision Making 3
...m that greatly simply taking high quality photomi...signed with real life in mind, the new PM30 system...scence photomicrography. In addition to their auto...l programs designed to easily cope with frustratin...
...lity at low light intensity. DFC350 F mono-chrome ... imaging applications where limited light is avail...vibrant images without noise or color aberrations....as allow dark and light objects to be recorded and...
... for the microscopist by the microscopy expert. No...mages in all image formats, it is also optimally a...grated with the software. What's more it also allo...ology guarantees that your working processes, from...
Leica DC300 FX
Medicine Products: